ER vs. IR [Design Issues]

posted by Dr_Dan  – 2019-12-19 09:01  – Posting: # 21004
Views: 555

Hi Helmut
your statement only holds true in your example with different strengths. If you have only one or the highest IR strength then my statement applies. The once daily (or 8 h) dosing of the ER formulation does not have to mimicry the performance of the multiple dosing of the IR formulation if you can show that there is a well-defined therapeutic window in terms of safety and efficacy and the rate of input is known not to influence the safety and efficacy profile or the risk for tolerance development.
KR
Dan

Kind regards and have a nice day
Dr_Dan

Complete thread:

Activity
 Admin contact
20,343 posts in 4,272 threads, 1,401 registered users;
online 14 (2 registered, 12 guests [including 6 identified bots]).
Forum time (Europe/Vienna): 21:01 CET

Every man gets a narrower and narrower field of knowledge
in which he must be an expert in order to compete with other people.
The specialist knows more and more about less and less
and finally knows everything about nothing.    Konrad Lorenz

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5